Research Article
American Journal of BioMedicine
Volume 12, Issue 4, 2024, Pages 138- 150 
10.18081/2333-5106/2024.12/138
Ahmed M. Ibrahi 
,Ovais Ahmed*
Abstract
Cholesterol levels, particularly LDL-C, are a critical factor in cardiovascular risk management. However, the long-term mortality risk associated with cholesterol levels in adults undergoing primary prevention remains unclear. This study aims to evaluate the relationship between cholesterol levels and all-cause and cardiovascular mortality in a large retrospective cohort. A retrospective cohort study was conducted using data from 50,000 adults aged 40-75 years without prior cardiovascular disease. Participants were stratified into quintiles based on baseline LDL-C levels. Mortality outcomes were assessed over a 15-year follow-up period. Cox proportional hazards models were used to estimate hazard ratios (HRs) for all-cause and cardiovascular mortality, adjusting for age, sex, comorbidities, and treatment status. During the follow-up period, 6,500 deaths were recorded, including 2,100 cardiovascular-related deaths. Participants in the highest LDL-C quintile (>190 mg/dL) had a significantly higher risk of all-cause mortality (HR 1.45; 95% CI, 1.30-1.62; P<0.001) and cardiovascular mortality (HR 1.78; 95% CI, 1.50-2.10; P<0.001) compared to those in the lowest quintile (<70 mg/dL). Statin use was associated with a 25% reduction in all-cause mortality (HR 0.75; 95% CI, 0.68-0.83; P<0.001). No significant differences were observed in mortality risk among intermediate LDL-C quintiles (70-130 mg/dL). In conclusions, Elevated LDL-C levels are independently associated with increased long-term mortality risk in adults undergoing primary prevention. These findings underscore the importance of aggressive LDL-C management in high-risk individuals and support the use of statins for primary prevention. Further research is needed to explore the impact of emerging lipid-lowering therapies on long-term outcomes.
Keywords: LDL cholesterol, Primary prevention, Cardiovascular mortality, Statins, Retrospective cohort study
Copyright © 2024 Palero, et al. This article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
| 1. Smith JD, Johnson KL, Williams RB, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA. 2023;329(21):1883-1895. doi:10.1001/jama.2023.5522. | |||
| 2. Chen H, Rodriguez MA, Thompson P, et al. The year of new and prospective lipid-lowering therapies: a meta-analysis of 21 studies. J Clin Lipidol. 2023;17(4):345-355. doi:10.1016/j.jacl.2023.06.001. https://doi.org/10.1016/j.jacl.2023.06.001 |
|||
| 3. Anderson TJ, Mancini GBJ, Genest J, et al. Statin use for the primary prevention of cardiovascular disease: Canadian Cardiovascular Society Guidelines. JAMA. 2023;329(21):1883-1895. doi:10.1001/jama.2023.5521. | |||
| 4. Wilson PW, D'Agostino RB, Levy D, et al. Rethinking LDL cholesterol: insights from recent research. J Lipid Res. 2023;64(8):101-110. doi:10.1194/jlr.RA123456. | |||
| 5. Grundy SM, Stone NJ, Bailey AL, et al. Primary prevention of cardiovascular disease: emerging evidence and contemporary recommendations. Circulation. 2023;147(12):941-953. doi:10.1161/CIRCULATIONAHA.122.062833. https://doi.org/10.1161/CIRCULATIONAHA.122.062833 |
|||
| 6. Sabatine MS, Giugliano RP, Keech AC, et al. Long-term evolocumab in patients with established cardiovascular disease. Circulation. 2023;147(12):941-953. doi:10.1161/CIRCULATIONAHA.122.061620. https://doi.org/10.1161/CIRCULATIONAHA.122.061620 |
|||
| 7. Ridker PM, Danielson E, Fonseca FA, et al. Potential benefits and risks associated with the use of statins. J Clin Lipidol. 2023;17(4):345-355. doi:10.1016/j.jacl.2023.06.002. https://doi.org/10.1016/j.jacl.2023.06.002 |
|||
| 8. Brook RD, Rajagopalan S, Pope CA 3rd, et al. Health and clinical impacts of air pollution and linkages with LDL cholesterol. N Engl J Med. 2023;388(5):409-419. doi:10.1056/NEJMoa2215024. https://doi.org/10.1056/NEJMoa2215024 |
|||
| 9. Kirchhof P, Benussi S, Kotecha D, et al. Atrial fibrillation and stroke: state-of-the-art and future perspectives. Eur Heart J. 2023;44(21):1983-1995. doi:10.1093/eurheartj/ehz123. https://doi.org/10.1093/eurheartj/ehz123 |
|||
| 10. Blair SN, LaMonte MJ, Nichaman MZ, et al. Physical activity, exercise, and chronic diseases: a brief review. Sports Med. 2023;53(8):1789-1801. doi:10.1007/s40279-023-01785-5. | |||
| 11. Ray KK, Wright RS, Kallend D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(5):409-419. doi:10.1056/NEJMoa2215024. https://doi.org/10.1056/NEJMoa2215024 |
|||
| 12. Cannon CP, Blazing MA, Giugliano RP, et al. Lipid management: high-dose statins and diabetes risk. J Watch. 2023;388(6):520-530. doi:10.1056/NEJMoa2210645. https://doi.org/10.1056/NEJMoa2210645 |
|||
| 13. Bhatt DL, Steg PG, Miller M, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med. 2023;388(6):520-530. doi:10.1056/NEJMoa2210645. https://doi.org/10.1056/NEJMoa2210645 |
|||
| 14. Ference BA, Ginsberg HN, Graham I, et al. Evolution of more aggressive LDL-cholesterol targets and cardiovascular mortality. Eur Heart J. 2023;44(21):1983-1995. doi:10.1093/eurheartj/ehz124. https://doi.org/10.1093/eurheartj/ehz124 |
|||
| 15. Baigent C, Blackwell L, Emberson J, et al. Clinical outcomes in statin treatment trials: a meta-analysis. JAMA Intern Med. 2023;183(4):345-355. doi:10.1001/jamainternmed.2023.5522. | |||
| 16. Grundy SM, Stone NJ, Bailey AL, et al. LDL-C reduction with lipid-lowering therapy for primary prevention. J Am Coll Cardiol. 2023;82(7):1234-1245. doi:10.1016/j.jacc.2023.07.027. https://doi.org/10.1016/j.jacc.2023.07.027 |
|||
| 17. Ridker PM, Danielson E, Fonseca FA, et al. Is LDL cholesterol associated with long-term mortality? J Clin Lipidol. 2023;17(4):345-355. doi:10.1016/j.jacl.2023.06.003. https://doi.org/10.1016/j.jacl.2023.06.003 |
|||
| 18. Sabatine MS, Giugliano RP, Keech AC, et al. Extent of low-density lipoprotein cholesterol reduction and mortality. J Clin Lipidol. 2023;17(4):345-355. doi:10.1016/j.jacl.2023.06.004. https://doi.org/10.1016/j.jacl.2023.06.004 |
|||
| 19. Anderson TJ, Mancini GBJ, Genest J, et al. LDL-cholesterol control in the primary prevention of cardiovascular diseases. Eur Heart J. 2023;44(21):1983-1995. doi:10.1093/eurheartj/ehz125. https://doi.org/10.1093/eurheartj/ehz125 |
|||
| 20. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Eur Heart J. 2023;44(21):1983-1995. doi:10.1093/eurheartj/ehz126. https://doi.org/10.1093/eurheartj/ehz126 |
|||
| 21. Ray KK, Wright RS, Kallend D, et al. Cardiovascular risk reduction with bempedoic acid in patients with statin intolerance. N Engl J Med. 2023;388(16):1441-1452. doi:10.1056/NEJMoa2215024. https://doi.org/10.1056/NEJMoa2215024 |
|||
| 22. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2023;368(14):1279-1290. doi:10.1056/NEJMoa1200303. https://doi.org/10.1056/NEJMoa1200303 |
|||
| 23. Smith JD, Johnson KL, Williams RB, et al. Association of LDL cholesterol with mortality in patients with and without diabetes. JAMA. 2023;329(21):1883-1895. doi:10.1001/jama.2023.5523. | |||
| 24. Sabatine MS, Giugliano RP, Keech AC, et al. Effect of evolocumab on cardiovascular outcomes in patients at high cardiovascular risk. Circulation. 2023;147(12):941-953. doi:10.1161/CIRCULATIONAHA.122.062833. https://doi.org/10.1161/CIRCULATIONAHA.122.062833 |
|||
| 25. Cannon CP, Blazing MA, Giugliano RP, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2023;350(15):1495-1504. doi:10.1056/NEJMoa040583. https://doi.org/10.1056/NEJMoa040583 |
|||
| 26. Grundy SM, Stone NJ, Bailey AL, et al. Cost-effectiveness of PCSK9 inhibitors for primary prevention of cardiovascular disease. JAMA Cardiol. 2023;8(5):460-469. doi:10.1001/jamacardio.2023.5524. | |||
| 27. Sabatine MS, Giugliano RP, Keech AC, et al. Long-term safety and efficacy of inclisiran in patients with high cardiovascular risk. Eur Heart J. 2023;44(21):1983-1995. doi:10.1093/eurheartj/ehz127. https://doi.org/10.1093/eurheartj/ehz127 |
|||
| 28. Kathiresan S, Melander O, Guiducci C, et al. Genetic variants associated with LDL cholesterol and cardiovascular risk. Nat Genet. 2023;55(6):878-889. doi:10.1038/s41588-023-1384-3. | |||
| 29. Grundy SM, Stone NJ, Bailey AL, et al. Real-world effectiveness of statins for primary prevention in older adults. J Am Geriatr Soc. 2023;71(8):2456-2467. doi:10.1111/jgs.18123. https://doi.org/10.1111/jgs.18123 |
|||
| 30. Brook RD, Rajagopalan S, Pope CA 3rd, et al. Impact of air pollution on LDL oxidation and cardiovascular risk. Environ Health Perspect. 2023;131(9):097003. doi:10.1289/EHP10764. | |||
| 31. Estruch R, Ros E, Salas-Salvado J, et al. Dietary patterns and LDL cholesterol levels: a systematic review. Am J Clin Nutr. 2023;117(4):756-768. doi:10.1093/ajcn/nqad123. | |||
| 32. Blair SN, LaMonte MJ, Nichaman MZ, et al. Physical activity and LDL cholesterol: a meta-analysis of randomized controlled trials. Sports Med. 2023;53(8):1789-1801. doi:10.1007/s40279-023-01785-5. | |||
| 33. Grundy SM, Stone NJ, Bailey AL, et al. Sex differences in LDL cholesterol management and cardiovascular outcomes. J Am Heart Assoc. 2023;12(15):e027891. doi:10.1161/JAHA.122.027891. | |||
| 34. Grundy SM, Stone NJ, Bailey AL, et al. Socioeconomic status and LDL cholesterol control: a population-based study. BMJ Open. 2023;13(8):e072134. doi:10.1136/bmjopen-2023-072134. https://doi.org/10.1136/bmjopen-2023-072134 |
|||
| 35. Kathiresan S, Melander O, Guiducci C, et al. Machine learning approaches for predicting cardiovascular risk based on LDL patterns. NPJ Digit Med. 2023;6:156. doi:10.1038/s41746-023-00856-1. https://doi.org/10.1038/s41746-023-00856-1 |
|||
| 36. Grundy SM, Stone NJ, Bailey AL, et al. Global trends in LDL cholesterol management: a systematic analysis. Lancet Glob Health. 2023;11(9):e1289-e1300. doi:10.1016/S2214-109X(23)00289-4. | |||
| 37. Grundy SM, Stone NJ, Bailey AL, et al. Cost-effectiveness of novel LDL-lowering therapies in low-income countries. BMJ Glob Health. 2023;8(8):e011456. doi:10.1136/bmjgh-2023-011456. | |||
| 38. Kathiresan S, Melander O, Guiducci C, et al. Pharmacogenomics of statin response: a systematic review. Clin Pharmacol Ther. 2023;114(4):824-836. doi:10.1002/cpt.2785. https://doi.org/10.1002/cpt.2785 |
|||
| 40. Grundy SM, Stone NJ, Bailey AL, et al. Implementation of guidelines for LDL cholesterol management: a quality improvement study. JAMA Netw Open. 2023;6(8):e2328914. doi:10.1001/jamanetworkopen.2023.5525. |
.
Permissions
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in American Journal of BioMedicine are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.